In a turning point for the U.S. cannabis industry, the Department of Health and Human Services (HHS) has issued a recommendation to reschedule marijuana to Schedule III under the Controlled Substances Act of 1970 (CSA). Historically, marijuana has been classified as a Schedule I controlled substance – a category defined as a substance with no accepted medical use and a high potential for abuse. This classification has been the subject of considerable criticism from advocates across the industry.
The move towards rescheduling comes after an instruction from President Biden in August 2022, requesting the U.S. Secretary of Health and Human Services to review how marijuana is scheduled under the CSA. The Act facilitates the regulation of substances under federal law into one of five classifications.
The potential rescheduling of marijuana shines a spotlight on the evolving legal landscape of the cannabis industry. Coupled with increased legislative support for cannabis legalization, the rescheduling of marijuana to Schedule III could have significant implications for businesses in the sector. Such implications could include potential taxation changes, shifts in medical usage, and alterations in the enforcement of criminal laws regarding cannabis.
As the situation develops, there remains an air of uncertainty regarding the full impact this change in scheduling may have on the industry.
You can find the full initial report by Neal, Gerber & Eisenberg LLP here.